| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10967626 | Vaccine | 2013 | 7 Pages |
Abstract
⺠First study of the final formulation of a bivalent rLP2086 vaccine in young adults. ⺠The vaccine was well tolerated; most AEs were not unusual for a vaccine trial. ⺠Most participants achieved hSBA titres â¥Â 1:4 against a panel of MnB target strains. ⺠hSBA MnB strains expressed diverse fHBP variants and suggest broad vaccine coverage. ⺠Data support further clinical development of the bivalent rLP2086 vaccine.
Keywords
Factor H-binding proteinNeisseria meningitidis serogroup BBacterial outer membrane proteinsmeningococcal serogroup BSerum bactericidal assayBactericidal antibodiesInvasive meningococcal diseaseUpper respiratory tract infectionAdverse eventsserious adverse eventsMeningococcalGeometric mean titreMeningococcal vaccinesFactor H binding protein
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Helen S. Marshall, Peter C. Richmond, Michael D. Nissen, Ann Wouters, James Baber, Qin Jiang, Annaliesa S. Anderson, Thomas R. Jones, Shannon L. Harris, Kathrin U. Jansen, John L. Perez,